Literature DB >> 7483805

Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.

J Weber1, R Cheinsong-Popov, D Callow, S Adams, G Patou, K Hodgkin, S Martin, F Gotch, A Kingsman.   

Abstract

In this Phase I study, immunisation with the yeast-derived p24 virus-like particles Ty p24-VLP (3 x 100 or 3 x 500 micrograms subcutaneously) in 16 healthy male subjects elicited p24 antibody responses in 4 of 16 (25%) subjects. After a fourth, intramuscular, immunisation (500 micrograms), p24 antibody responses were detected in 11 of 15 (70%) subjects. In addition to p24 antibody responses, T cell proliferative responses were also observed, although no HLA restricted p24-specific cytotoxic T cell responses were detected. The results demonstrate that Ty p24-VLP is immunogenic and well-tolerated in healthy male subjects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7483805     DOI: 10.1016/0264-410x(94)00061-q

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Virus-like particles as vaccine adjuvants.

Authors:  S C Gilbert
Journal:  Mol Biotechnol       Date:  2001-10       Impact factor: 2.695

2.  Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

Authors:  C Sedlik; M Saron; J Sarraseca; I Casal; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

3.  Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.

Authors:  J Weber; E M Fenyö; S Beddows; P Kaleebu; A Björndal
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.

Authors:  Natasha Larke; Aileen Murphy; Christoph Wirblich; Denise Teoh; Marie J Estcourt; Andrew J McMichael; Polly Roy; Tomás Hanke
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.

Authors:  T Hanke; R V Samuel; T J Blanchard; V C Neumann; T M Allen; J E Boyson; S A Sharpe; N Cook; G L Smith; D I Watkins; M P Cranage; A J McMichael
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice.

Authors:  Shuo Zhang; Mifang Liang; Wen Gu; Chuan Li; Fang Miao; Xiaofang Wang; Cong Jin; Li Zhang; Fushun Zhang; Quanfu Zhang; Lifang Jiang; Mengfeng Li; Dexin Li
Journal:  Virol J       Date:  2011-06-30       Impact factor: 4.099

Review 7.  Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.

Authors:  Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

Review 8.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

9.  Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.

Authors:  Lishan Lv; Xiaoming Li; Genmei Liu; Ran Li; Qiliang Liu; Huifang Shen; Wei Wang; Chunyi Xue; Yongchang Cao
Journal:  J Vet Sci       Date:  2013-12-27       Impact factor: 1.672

Review 10.  Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.

Authors:  Zeinab Shirbaghaee; Azam Bolhassani
Journal:  Biopolymers       Date:  2016-03       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.